Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Unfolded Protein Response (UPR) Targeted Development in Oncology, Neurodegeneration, and Metabolic Disease.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EIF2AK3/PERK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase (WT/Mutant) | EIF2AK3 Kinase Domain, high purity (>95%), ATP-binding verified, endotoxin <1EU/μg. Sequence and folding verified (HEK293/Sf9 expression). | View EIF2AK3 Products |
| Gene Delivery | EIF2AK3-PERK Lentivirus Particles, full-length ORF for stable cell lines, high titer (>1x10^8 TU/ml). | View EIF2AK3 Products |
| Benchmark Ab (Anti-EIF2AK3) | Recombinant positive control antibody for EIF2AK3 detection. | View EIF2AK3 Products |
| Phospho-Validator (Anti-p-eIF2α Ser51) | Recombinant antibody for substrate phosphorylation readout. | View EIF2S1 Products |
| Knockdown Validator | EIF2AK3 siRNA Set (3 unique sequences) for specificity checks and loss-of-function studies. | View EIF2AK3 Products |
| Off-Target Control | EIF2AK4/GCN2 Kinase Domain for selectivity screening. | View EIF2AK4 Products |
| Pathway Partner | ATF4 Recombinant Protein, downstream transcription factor for reporter assays. | View ATF4 Products |
| Parallel UPR Branch | ERN1 (IRE1a) – combination therapy target. | View ERN1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Activity & Conformation Stability | HEK293/Sf9 expressed kinase domain with native folding; >95% purity; endotoxin <1EU/μg; high ATP-binding capacity. |
| EIF2AK Family Selectivity (GCN2/PKR/HRI off-target) | Paralog panel available: EIF2AK4 (GCN2), EIF2AK2 (PKR), EIF2AK1 (HRI) kinase domains, >95% purity, mass spec verified. |
| Cellular UPR Context Assay | Lentivirus premade particles for stable PERK-overexpression; compatible with ER stress reporters. |
| Lack of Controls | Clinical benchmark antibodies included (anti-EIF2AK3 and anti-p-eIF2α). |
| False Positives | Validated siRNA set included for specificity verification. |
| Resistance Mutation Profiling | Custom mutant generation service (e.g., gatekeeper mutations, ATP-pocket variants); sequence verified. |
Live EIF2AK3/PERK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials (EIF2AK3)
- View Active Clinical Trials (PERK Inhibitor)
- Latest Resistance Research
- Recent Patent Filings (EIF2AK3)
- Recent Patent Filings (PERK Inhibitor)
Key Mutations & Functional Domains
EIF2AK3 (PERK) contains a protein kinase domain (UniProt Q9NZJ5). Key mutations documented include a variant in WRS (VAR_089927), and variants in dbSNP:rs867529 (VAR_011409) and dbSNP:rs13045 (VAR_011410). These mutations are relevant for resistance profiling and genetic association studies.
Global Clinical Landscape & Future Outlook
The PERK inhibitor landscape is transitioning from broad cytoprotection to precision indications. Major players such as GSK (GSK2606414/GSK2656157), Calithera Biosciences, and Amgen have advanced Phase I/II assets. A key challenge is the narrow therapeutic window due to pancreatic toxicity (β-cell dysfunction). The next wave of R&D is focusing on CNS-penetrant selective inhibitors for neurodegeneration (ALS, Alzheimer's, Parkinson's) and combination strategies with proteasome inhibitors in multiple myeloma. Differentiation now depends on exquisite selectivity over GCN2 and PKR, combined with resistance mutation profiling to preempt clinical failure. First-generation ATP-competitive inhibitors are giving way to highly selective kinase inhibitors, PROTAC degraders, and allosteric modulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | GSK, Calithera, Amgen | Solid Tumors, Multiple Myeloma | Biochemical Kinase Assay (active WT/Mutant domains required) |
| CNS-Penetrant Inhibitor | Various Biotech | ALS, Alzheimer's, TBI | Cell-Based UPR Reporter (lentivirus-stable lines for p-eIF2α readout) |
| PROTAC Degrader | Emerging Academic | Resistant Tumors | Full-length PERK Expression (lentivirus for protein level control) |
| Combination Therapy | Academic Consortia | Immunotherapy combos | Pathway Validation (validated siRNA for specificity) |
| Selectivity Profiling | All Developers | Safety Assessment | Paralog Kinase Panel (EIF2AK4/GCN2, EIF2AK2/PKR, EIF2AK1/HRI) |